Abstract
The structural diversity of β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors was expanded by harnessing diverse building blocks that had been prepared via a unified lead-oriented synthetic approach. It was shown that the lipophilic cyclohexylmethyl group within a known series of BACE1 inhibitors could be productively replaced with a range of alternative ring systems.
Funding Information
  • Engineering and Physical Sciences Research Council (EP/N025652/1)
  • Takeda Pharmaceuticals North America (NA)
  • University of Leeds

This publication has 21 references indexed in Scilit: